跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
克韦滋 - NMPA Drug Approval Details
Approvals
/
NMPA
/
Abacavir and Lamivudine Tablets
Approved
化学药品
Abacavir and Lamivudine Tablets
Glaxosmithkline Pharmaceuticals SA
🇨🇳 National Medical Products Administration
Approval Date
Nov 7, 2016
Approval ID
7MazXcP1IhC
Company
Glaxosmithkline Pharmaceuticals SA
Type
化学药品
Approval Details
Approval Id
7MazXcP1IhC
Approval Number
H20160572
Generic Name
阿巴卡韦拉米夫定片
Generic Name En
Abacavir and Lamivudine Tablets
Trade Name
克韦滋
Drug Type
化学药品
Dosage Form
片剂
Strength
每片含阿巴卡韦600 mg (硫酸盐)和拉米夫定300 mg
Reg Date
2016-11-07
Expired Date
2021-11-06
Company Name
Glaxosmithkline Pharmaceuticals SA
Company Address
980 Great West Road, Brentford, Middlesex TW8 9GS, United Kingdom
Production Company Name
Glaxosmithkline Pharmaceuticals SA
Production Company Address
ul. Grunwaldzka 189, 60-322 Pozna, Poland
Company Detail Path
/organization/glaxosmithkline-pharmaceuticals-sa
Production Company Detail Path
/organization/glaxosmithkline-pharmaceuticals-sa
Approved
Quick Info
Agency
NMPA
Country
🇨🇳
Approval Date
Nov 7, 2016
Approval ID
7MazXcP1IhC
Type
化学药品
Back to NMPA Approvals